FDA approves new nasal spray to treat migraines

Image credit: simonkadula via Unsplash

The U.S. Food and Drug Administration (FDA) has recently approved a new nasal spray designed to treat migraines in adults. This breakthrough nasal spray named Zavzpret was developed by the renowned biopharmaceutical company Pfizer, and is expected to be available in pharmacies across the country beginning July 2023. In a recently published Lancet Neurology study, the authors demonstrated effectiveness in treating migraines with Zavzpret, showing positive tolerability and safety profiles among participants. This significant development in migraine treatment offers patients, particularly those with heart disease, a promising solution to alleviate their symptoms and enhance their overall quality of life.

Source

Goodman, Brenda. “FDA Approves New Nasal Spray to Treat Migraine Headaches in Adults, Pfizer Says.” CNN, 10 Mar. 2023, www.cnn.com/2023/03/10/health/migraine-nasal-spray-zavzpret/index.html#:~:text=The%20US%20Food%20and%20Drug,said%20in%20a%20news%20release.